| Document |
Document Title |
|
WO/2022/219080A1 |
The present invention relates to the treatment of cancer and particularly the neuroblastoma. The inventors focused for many years on immunotherapeutic strategies targeting the O-acetylated form of GD2 (OAcGD2), which they believed could ...
|
|
WO/2022/218040A1 |
The present application relates to use of a reagent targeting a GSDME pathway in preparation of a drug for treating pancreatic cancer. By targeting the member acting on the GSDME pathway, such as GSDME, MUC 1, or MUC 13, it can break the...
|
|
WO/2022/218437A1 |
The present invention relates to a lamotrigine hydrate crystal form, a preparation method therefor and a composition containing same, and particularly relates to a lamotrigine hydrate form A, a preparation method therefor and a compositi...
|
|
WO/2022/221566A1 |
Disclosed herein are methods and kits for identifying responsiveness or non-responsiveness of a cancer subject to arginine deprivation therapy. The method includes determining the presence of a G/G genotype of rs13338697 of the target nu...
|
|
WO/2022/220147A1 |
The present invention provides a muscle atrophy inhibition composition. Specifically, the present invention provides a muscle atrophy inhibitor that includes a CXCL10 expression inhibitor as an active ingredient.
|
|
WO/2022/218288A1 |
Disclosed in the present invention is a method for preparing an antibody-drug conjugate. Specifically, the preparation method comprises the following steps: (a) providing a mutant antibody comprising two reactive groups, wherein one of t...
|
|
WO/2022/011132A9 |
Combination dosage forms of anti-cancer products include components a) and b), where component a) comprises individual amounts of curcumin, harmine, isovanillin, and component b) comprises an agent selected from the group consisting of E...
|
|
WO/2022/221886A1 |
Provided herein are pharmaceutical compositions for the treatment of benign prostatic hypertrophy comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones. Further p...
|
|
WO/2022/221401A1 |
The present application relates to formulations comprising a combination of an NAD+ agonist and a flavonoid polyphenol. Also provided herein are methods of administering a combination of an NAD+ agonist and a flavonoid for use in methods...
|
|
WO/2022/221613A1 |
Pharmaceutical compositions comprising a norepinephtrine reuptake inhibitor (NRI) and a cannabinoid and optionally a muscarinic receptor antagonist (MRA) and/or carbonic anhydrase inhibitor (CAI) and methods of treating sleep apnea are d...
|
|
WO/2022/221546A1 |
Provided is a method of treating a neurological or psychiatric disease or disorder in a patient in need thereof, comprising: administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to the patient in need thereof, the patient ...
|
|
WO/2022/219021A1 |
Cation chloride cotransporters (CCC) play a critical role in neuronal chloride homeostasis. Altered CCC expression and function has emerged as a hallmark of wide range of psychiatric and neurological conditions, including various forms o...
|
|
WO/2022/218335A1 |
The present invention relates to a Lactobacillus reuteri, and a use, composition, drug and food thereof. The present Lactobacillus reuteri has the preservation number of CGMCC No. 21577, can improve intestinal flora disorder, reduce inte...
|
|
WO/2022/219076A1 |
The present invention relates to the treatment of cancer and particularly the neuroblastoma. In thus study, the inventors hypothesized that CD47 expression would interfere with the contribution of macrophage to the therapeutic effect of ...
|
|
WO/2022/221304A1 |
Provided are methods for treating, mitigating, or preventing or delaying the recurrence or metastasis of, a cancer in a subject comprising co-administering: (a) an agent that inhibits binding between CD47 and SIRPα; and (b) a NEDD8-acti...
|
|
WO/2022/216648A1 |
This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with KRASG12C inhibitors.
|
|
WO/2022/217287A1 |
Disclosed herein in certain implementations are formulations and methods relating to an alternative formulation of medication for the treatment of ADHD based on two principles: (a) retaining the initial immediate-release component of con...
|
|
WO/2022/214873A1 |
The invention provides devices and their use for removal of citrullinated histones and neutrophil extracellular traps (NETs) from patients' blood, to limit the negative effects of circulating citrullinated histones and NETs and to treat ...
|
|
WO/2022/216944A1 |
Methods and materials for treating atherosclerosis are provided herein. For example, methods and materials for using one or more IGF-1 signaling pathway modulators to treat atherosclerosis by increasing fibrous cap thickness, promoting f...
|
|
WO/2022/216379A1 |
The present disclosure relates to methods of treating certain diseases and disorders (e.g., cancer) with a combination of an IRAK4 inhibitor, a BCL-2 inhibitor, and a nucleoside analog.
|
|
WO/2022/214025A1 |
Disclosed in the present invention are a pegylated lipid, a preparation method therefor, a liposome containing the pegylated lipid, a pharmaceutical composition containing the liposome, a preparation thereof, and the use thereof, belongi...
|
|
WO/2022/217095A1 |
Disclosed are methods and related compositions for administering a high affinity IL-2 receptor agonist in combination with immunosuppressants. The methods and compositions provided can be used for enhancing regulatory T cells, including ...
|
|
WO/2022/216903A1 |
Aspects of the disclosure provide methods for inhibiting cell proliferation and protein synthesis utilizing an antagonist of nicotinamide adenine dinucleotide kinase 2 (NADK2). In some aspects, these methods are used to treat a disease s...
|
|
WO/2022/215754A1 |
Provided is a bicyclic pyridine derivative. A compound represented by formula I [wherein: X represents an oxygen atom, a sulfur atom, NR or CR'R"; n is 0 or 1; R1, R2a, R2b, R2c, R2d, R, R' and R" independently represent a hydrogen atom,...
|
|
WO/2022/150540A9 |
Compositions for intranasal delivery of benzodiazepines and methods for their use to treat and prevent seizures are provided. The compositions deliver rapid therapeutic onset with a decreased incidence and/or severity of adverse effects ...
|
|
WO/2022/216845A1 |
The disclosure provides compositions and methods for the treatment of hearing loss disorder.
|
|
WO/2022/216184A1 |
The present invention relates to the use of antibody to PD-1, in particular prolgolimab, in combination with at least one chemotherapeutic agent, in particular paclitaxel, carboplatin or cisplatin, for treating a malignant neoplasm in a ...
|
|
WO/2022/216645A1 |
This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with CDK4/6 inhibitors.
|
|
WO/2022/216965A1 |
Provided are methods for treating a solid cancer in a subject by administering an effective amount of a radioconjugated CCR8-targeting agent to deplete tumor-associated CCR8-positive Treg cells, alone or in combination with one or more a...
|
|
WO/2022/213895A1 |
The present invention provides a novel cationic lipid having a structure as shown in general formula (1) and particularly relates to a nitrogen-branched cationic lipid, and also relates to a liposome containing the cationic lipid, and a ...
|
|
WO/2022/216979A1 |
The synthesis and use of radiolabeled derivatives of poly-(ADP-ribose) (PARP) inhibitors in positron emission tomography (PET) imaging methods are disclosed. A novel non-radioactive analogue of the PARP inhibitor Talazoparib (TZ) provide...
|
|
WO/2022/214026A1 |
Disclosed in the present invention are a pegylated lipid and a preparation method therefor, a liposome comprising the pegylated lipid, and a pharmaceutical composition comprising the liposome and a preparation and use thereof, relating t...
|
|
WO/2022/217066A1 |
New methods, compositions and kits that comprise perampanel are provided for treating a subject having a SYNGAP1 neurodevelopmental disorder, including to treat conditions of sleep disorder, behavior problems and/or myoclonic or reflex s...
|
|
WO/2022/214455A1 |
The invention relates to compositions for the improvement of sport performance comprising Leucine, Isoleucine, Valine, Arginine and Glutamine, compounds of formula (I) and at least one acceptable carrier.
|
|
WO/2022/217068A1 |
Provided herein are methods of use a cyclin dependent kinase (CDK) inhibitor for the treatment of leukemia. The CDK inhibitor described herein include NU6027. The methods described herein include methods of treatment of drug-resistant le...
|
|
WO/2022/177962A9 |
The present disclosure relates to solid and liquid formulations of RUC-4 that are stable under a range of storage conditions.
|
|
WO/2022/213878A1 |
Disclosed in the present invention is a drug Ramipril (Altace) targeting an SOAT1 protein. Experiments show that the drug is the same as a positive control drug nevanimibe, and can be combined with SOAT1 so as to inhibit cholesterol from...
|
|
WO/2022/213562A1 |
The present invention relates to a cell gel preparation, which is used for treating and/or preventing acute or chronic osteoarthritis and/or symptoms thereof by means of intra-articular injection, wherein the preparation comprises a nucl...
|
|
WO/2022/217123A2 |
The present disclosure relates to combination therapies with Cbl-b inhibitor compounds, and compositions and kits comprising combinations with the Cbl-b compounds. Also provided are methods of using the combinations with Cbl-b compounds ...
|
|
WO/2022/217199A1 |
Disclosed herein are dosing regimens of ceftibuten in combination with a β-lactamase inhibitor. The dosing regimens include ceftibuten at a dose higher than 400 mg per day (for example, 400 mg BID, 600 mg QD or BID, or 800 mg QD or BID).
|
|
WO/2022/217145A1 |
Examples disclosed herein may involve a computing system that is configured to (i) identify a cannabinoid formulation for which to model efficacy for a given health condition shared by a plurality of individuals, (ii) receive respective ...
|
|
WO/2022/216719A1 |
Combination therapies comprising belvarafenib and cobimetinib and comprising belvarafenib, cobimetinib, and atezolizumab are provided for the treatment of melanoma carrying a NRAS mutation.
|
|
WO/2022/210644A1 |
The present disclosure provides virus suppression by a nucleolus-modifying agent. One aspect of the present disclosure provides an antivirus agent effective against a corona virus, the agent having a nucleolus-modifying agent as an activ...
|
|
WO/2022/211508A1 |
The present invention relates to: a novel antibody-drug conjugate (ADC) targeting claudin 18 isoform 2 (CLDN18.2); an active metabolite of the ADC; a method for producing the ADC; a use of the ADC for treating and/or preventing diseases;...
|
|
WO/2022/208369A1 |
A composition comprising at least two different strains of isolated bacteriophages, each capable of infecting a bacteria of the species Pseudomonas aeruginosa, wherein at least one of said at least two different strains of isolated bacte...
|
|
WO/2022/206976A1 |
Provided is an isolated antigen-binding protein capable of binding to CLDN18.2. Also included is a chimeric antigen receptor of the isolated antigen-binding protein. Further provided are a method for preparing the antigen-binding protein...
|
|
WO/2022/207860A2 |
The present invention relates to the combination of a Selective Estrogen Receptor Modulator (SERM) and a COVID-19 vaccine.
|
|
WO/2022/206250A1 |
Disclosed is a use of an alkaloid compound in the preparation of a product for preventing and/or treating cardiac injury. An activity study was conducted on the alkaloid compound, which verified that the alkaloid compound provided in the...
|
|
WO/2022/210802A1 |
The purpose of the present invention is to provide a novel agent for the prevention or treatment of muscular atrophy. The present invention provides an agent for the prevention or treatment of muscular atrophy, wherein the agent contains...
|
|
WO/2022/212365A1 |
The present disclosure provides methods of treating or preventing a SARS-CoV-2 infection or a SARS-CoV-2-infection associated disease or disorder (e.g. COVID-19) comprising administering to a subject in need thereof an effective amount o...
|
